A Study to Evaluate Pharmcokinetics, Pharmacodynamics , Efficacy and Safety of 6MW3211 Monotherapy and in Combination With Azacitidine(AZA) or AZA Plus Venetoclax(VEN) in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Latest Information Update: 16 Mar 2023
At a glance
- Drugs 6MW 3211 (Primary) ; Azacitidine; Venetoclax
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Mabwell (Shanghai) Bioscience
- 13 Mar 2023 New drugs added to the treatment Azacitidine(AZA) or AZA Plus Venetoclax(VEN)
- 13 Mar 2023 Planned number of patients changed from 30 to 120.
- 13 Mar 2023 Planned End Date changed from 31 Dec 2023 to 1 Oct 2024.